
As part of a team that included physician-scientists, biomedical engineers and students, Ivan Nenadic, Ph.D., brought the math to help transplant patients know more about their new organ with fewer needles.
Ivan Nenadic, Ph.D., is equipped with dišpet, a Croatian word that means perseverance bordering on defiance.
“It’s inherent in our people,” says Dr. Nenadic, who grew up in war-torn Yugoslavia. “When facing an obstacle, you don’t get rattled. You have composure under pressure, remain level headed, and decide what’s the next step. There’s a strong faith in a better tomorrow.”
Dišpet explains much. Like how 17-year-old Ivan left home in Serbia, moving to the United States for a career in science, how ultimately, his efforts helped create a noninvasive imaging alternative to needle biopsy; and why this doctorate-level scientist is going back to school to become a physician.
Coming to America
“It’s known around the world that, if you want to do something serious in science, you go to the U.S.,” Dr. Nenadic says.
He landed in Rochester, Minnesota, as a 17-year-old foreign-exchange student hosted by Douglas Wood, M.D., a cardiologist, internist and medical director of Mayo Clinic Center for Innovation; and Julia Wood, a former nurse at Mayo Clinic. They soon became his second stand-in set of parents.
“I was not interested in medicine until I was essentially adopted by the Wood family,” Dr. Nenadic recalls. “I was beginning to understand that there’s a lot more to it than solving a medical question. You’re trying to help patients achieve a happy life.” Read the rest of the article on Discovery's Edge.
_________________________________________________________
Other Mayo Clinic medical research websites:
The holiday season can invite unwelcome guests into your life, such as loneliness, money problems, family demands and unrealistic expectations. The stress and anxiety that ...
National Handwashing Awareness Week will be observed Dec. 3–9, so this is a good time for a reminder that washing your hands is one of the ...
The Food and Drug Administration is expected to decide by Dec. 8 on a new therapy to treat sickle cell disease using gene editing technology called CRISPR, ...